Is there a Role for Neoadjuvant Targeted Therapy and Immunotherapy?
(2021) Critical issues in head and neck oncology — ISBN: [9783030632335], p. 193-203, published
Files
978-3-030-63234-2_13.pdf
Open Access - Adobe PDF
- 325.3 KB
Details
- Authors
- Abstract
- Neoadjuvant chemotherapy in head and neck cancer is the subject of much debate. Multiple trials have shown that the concomitant addition of targeted therapies, such as cetuximab to neoadjuvant chemotherapy (docetaxel, cisplatin, 5-fluorouracil), results in increased toxicity. Furthermore, no apparent significant benefit has been demonstrated in small randomized studies. Additional trials are currently being conducted to investigate the role of neoadjuvant immunotherapy, such as anti-PD-(L)1 inhibitors. On the other hand, window of opportunity studies are trials in which patients receive one investigational compound in the period between their cancer diagnosis and the start of standard therapy. The evaluation of new compounds using this approach enables translational research and provides information on molecular and clinical activity as well as predictive biomarkers.
- Affiliations
Citations
Beyaert, S., & Machiels, J.-P. (2021). Is there a Role for Neoadjuvant Targeted Therapy and Immunotherapy? In Jan B. Vermoken, Volker Budach, C. René Leemans e.a. (ed.), Critical issues in head and neck oncology (p. p. 193-203). Springer, Cham. https://doi.org/10.1007/978-3-030-63234-2_13